The Developmental Therapeutics Program evolved from the more basic Cell Cycling and Signaling Program, which scored "Outstanding" in prior renewal cycles ofthis Helen Diller Family Comprehensive Cancer Center support grant. The research themes ofthe Cell Cycling and Signaling Program were related to identification and validation of therapeutic targets. Many of these targets have subsequently moved into preclinical testing or are ready to be explored in early-stage clinical trials. The new Eariy Phase Clinical Trials Unit has created an ideal opportunity to translate these themes effectively, through the design and analysis of innovative research protocols. The Program comprises 32 members involving 13 different departments and brings together basic cancer biologists and physician scientists with the common goal of discovering and testing novel compounds and treatment strategies for cancer The Program themes are: 1) Targeting signal transduction pathways (RTKs, RAS, RAF/MAPK, Pl 3'kinase, and wnt) 2) Targeting DNA replication and genome integrity (cell cycle, telomerase, HDAC) 3) Angiogenesis 4) Apoptosis 5) Genetic determinants of sensitivity and resistance The wide range of expertise ofthe Program members will mutually enrich and complement the discoveries of individual investigators with the overall Program goal being to accelerate the transition from drug discovery to the approval of more effective and less toxic drugs for patients with cancer. Research in the Program spans from drug discovery, cell signaling, molecular pathology and bioimaging to pharmacogenomics, as well as clinical and population science with recent high impact publications in Nature, Nature Medicine, Nature Genetics, New England Journal of Medicine, Journal of Clinical Oncology, Journal of Biological Chemistry, JAMA, Proceedings of the National Academy of Science of the United States, and The Lancet. The Program has a sizable and increasing percentage of intra- and inter-programmatic publications, which reflect the thematic breadth of the work and the emerging efforts of strategic integration of its members. The Program had $7,271,609 total peer-reviewed support for the last budget year. The Program has 12% intra-programmatic and 13% inter-programmatic publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693940
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$143
Indirect Cost
$53
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
John, Constance M; Phillips, Nancy J; Din, Richard et al. (2016) Lipooligosaccharide Structures of Invasive and Carrier Isolates of Neisseria meningitidis Are Correlated with Pathogenicity and Carriage. J Biol Chem 291:3224-38
Shatsky, Maxim; Dong, Ming; Liu, Haichuan et al. (2016) Quantitative Tagless Copurification: A Method to Validate and Identify Protein-Protein Interactions. Mol Cell Proteomics 15:2186-202
Nordström, Tobias; Van Blarigan, Erin L; Ngo, Vy et al. (2016) Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 76:339-48
Bulut-Karslioglu, Aydan; Biechele, Steffen; Jin, Hu et al. (2016) Inhibition of mTOR induces a paused pluripotent state. Nature 540:119-123
Akutagawa, J; Huang, T Q; Epstein, I et al. (2016) Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia 30:1335-43
Baeza-Raja, Bernat; Sachs, Benjamin D; Li, Pingping et al. (2016) p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. Cell Rep 14:255-68
Ko, Andrew H; Bekaii-Saab, Tanios; Van Ziffle, Jessica et al. (2016) A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res 22:61-8
Nosbaum, Audrey; Prevel, Nicolas; Truong, Hong-An et al. (2016) Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. J Immunol 196:2010-4
Phan, An T; Fernandez, Samantha G; Somberg, Jessica J et al. (2016) Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels. Biochem Biophys Res Commun 474:71-5
Chang, Matthew T; Asthana, Saurabh; Gao, Sizhi Paul et al. (2016) Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34:155-63

Showing the most recent 10 out of 135 publications